ES2332416T3 - Ligandos de receptores cannabinoides. - Google Patents

Ligandos de receptores cannabinoides. Download PDF

Info

Publication number
ES2332416T3
ES2332416T3 ES05766578T ES05766578T ES2332416T3 ES 2332416 T3 ES2332416 T3 ES 2332416T3 ES 05766578 T ES05766578 T ES 05766578T ES 05766578 T ES05766578 T ES 05766578T ES 2332416 T3 ES2332416 T3 ES 2332416T3
Authority
ES
Spain
Prior art keywords
group
alkyl
cycloalkyl
baselineskip
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05766578T
Other languages
English (en)
Spanish (es)
Inventor
Bandarpalle B. Shankar
Eric Gilbert
Razia K. Rizvi
Chunli Huang
Joseph A. Kozlowski
Stuart Mccombie
Neng-Yang Shih
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2332416T3 publication Critical patent/ES2332416T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/20—Spiro-condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES05766578T 2004-06-22 2005-06-21 Ligandos de receptores cannabinoides. Expired - Lifetime ES2332416T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58183704P 2004-06-22 2004-06-22
US581837P 2004-06-22

Publications (1)

Publication Number Publication Date
ES2332416T3 true ES2332416T3 (es) 2010-02-04

Family

ID=35079285

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05766578T Expired - Lifetime ES2332416T3 (es) 2004-06-22 2005-06-21 Ligandos de receptores cannabinoides.

Country Status (10)

Country Link
US (1) US7750158B2 (show.php)
EP (1) EP1768667B1 (show.php)
JP (1) JP2008503585A (show.php)
CN (1) CN101005838A (show.php)
AT (1) ATE444066T1 (show.php)
CA (1) CA2571058A1 (show.php)
DE (1) DE602005016929D1 (show.php)
ES (1) ES2332416T3 (show.php)
MX (1) MX2007000015A (show.php)
WO (1) WO2006002133A1 (show.php)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101304997A (zh) * 2005-08-19 2008-11-12 伊兰医药品股份有限公司 γ-分泌酶的桥联N-二环磺酰氨基抑制剂
CA2651777A1 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Pro-drugs of tertiary alcohols
CA2674644A1 (en) 2007-01-10 2008-07-17 F. Hoffmann-La Roche Ag Sulfonamide derivatives as chymase inhibitors
EP2131655B1 (en) 2007-03-02 2014-05-07 The University of Tennessee Research Foundation Tri-aryl/heteroaromatic cannabinoids and use thereof
EP2336125B1 (en) 2008-04-11 2013-01-09 Janssen Pharmaceutica N.V. Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
FR2945531A1 (fr) * 2009-05-12 2010-11-19 Sanofi Aventis Derives de 7-aza-spiro°3,5!nonane-7-carboxylates, leur preparation et leur application en therapeutique
BRPI1012205A2 (pt) 2009-05-14 2019-04-02 Janssen Pharmaceutica Nv compostos com duas porções heteroarila bicíclica fundidas como moduladores de leucotrieno a4 hidrolase
BR112013007566A2 (pt) 2010-09-28 2016-08-02 Panacea Biotec Ltd novos compostos bicíclicos
GB201103419D0 (show.php) * 2011-02-28 2011-04-13 Univ Aberdeen
MX359634B (es) 2011-12-21 2018-10-03 Novira Therapeutics Inc Agentes antivirales contra la hepatitis b.
UY34992A (es) 2012-08-28 2014-02-28 Janssen R & D Ireland Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
PT2961732T (pt) 2013-02-28 2017-06-26 Janssen Sciences Ireland Uc Sulfamoil-arilamidas e utilização das mesmas como medicamentos para o tratamento de hepatite b
WO2014165128A2 (en) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Hepatitis b antiviral agents
WO2014161888A1 (en) 2013-04-03 2014-10-09 Janssen R&D Ireland N-phenyl-carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
PT2997019T (pt) 2013-05-17 2018-11-21 Janssen Sciences Ireland Uc Derivados de sulfamoíltiofenamida e o seu uso como medicamentos para o tratamento da hepatite b
UA118680C2 (uk) 2013-07-25 2019-02-25 ЯНССЕН САЙЄНСЕЗ АЙРЛЕНД ЮСі Похідні заміщеного гліоксамідом піроламіду та їхнє застосування як лікарських препаратів для лікування гепатиту в
EP3060547B1 (en) 2013-10-23 2017-10-11 Janssen Sciences Ireland UC Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
RU2702109C1 (ru) 2014-02-05 2019-10-04 Новира Терапьютикс, Инк. Комбинированная терапия для лечения инфекций вгв
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
AU2016232801A1 (en) 2015-03-19 2017-10-12 Novira Therapeutics, Inc. Azocane and azonane derivatives and methods of treating hepatitis B infections
CN104898325A (zh) * 2015-05-18 2015-09-09 深圳市华星光电技术有限公司 一种液晶显示面板及装置
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AR106192A1 (es) 2015-09-29 2017-12-20 Novira Therapeutics Inc Formas cristalinas de un agente antiviral contra la hepatitis b
SG11201808949SA (en) 2016-04-15 2018-11-29 Novira Therapeutics Inc Combinations and methods comprising a capsid assembly inhibitor
EP3749667A1 (en) 2018-02-05 2020-12-16 Alkermes, Inc. Compounds for the treatment of pain
WO2019175657A1 (en) 2018-03-14 2019-09-19 Janssen Sciences Ireland Unlimited Company Capsid assembly modulator dosing regimen
CN113454077A (zh) 2019-02-22 2021-09-28 爱尔兰詹森科学公司 用于治疗hbv感染或hbv诱发的疾病的酰胺衍生物
MA55879A (fr) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Co Dérivés d'amide utiles dans le traitement d'une infection par le virus de l'hépatite b ou de maladies induites par le virus de l'hépatite b
KR20220034739A (ko) 2019-05-31 2022-03-18 이케나 온콜로지, 인코포레이티드 Tead 억제제 및 이의 용도
WO2020243415A2 (en) 2019-05-31 2020-12-03 Ikena Oncology, Inc. Tead inhibitors and uses thereof
CN112516138B (zh) * 2020-12-15 2022-03-29 中国人民解放军陆军军医大学 化合物yx-2102在制备治疗肺纤维化药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5338753A (en) * 1992-07-14 1994-08-16 Sumner H. Burstein (3R,4R)-Δ6 -tetrahydrocannabinol-7-oic acids useful as antiinflammatory agents and analgesics
FR2714057B1 (fr) * 1993-12-17 1996-03-08 Sanofi Elf Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant.
IT1271266B (it) * 1994-12-14 1997-05-27 Valle Francesco Della Impiego terapeutico di ammidi di acidi mono e bicarbossilici con amminoalcoli,selettivamente attive sul recettore periferico dei cannabinoidi
US5532237A (en) * 1995-02-15 1996-07-02 Merck Frosst Canada, Inc. Indole derivatives with affinity for the cannabinoid receptor
FR2735774B1 (fr) * 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
FR2742148B1 (fr) * 1995-12-08 1999-10-22 Sanofi Sa Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant
CA2245586A1 (en) * 1996-02-06 1997-08-14 Japan Tobacco Inc. Novel compounds and pharmaceutical use thereof
WO1998041519A1 (en) * 1997-03-18 1998-09-24 Smithkline Beecham Corporation Novel cannabinoid receptor agonists
TW200302088A (en) * 2001-11-14 2003-08-01 Schering Corp Cannabinoid receptor ligands
MXPA06004279A (es) 2003-10-14 2006-06-28 Pfizer Prod Inc Derivados biciclicos [3.1.0] como inhibidores del transportador de glicina.

Also Published As

Publication number Publication date
ATE444066T1 (de) 2009-10-15
EP1768667A1 (en) 2007-04-04
MX2007000015A (es) 2007-03-07
US7750158B2 (en) 2010-07-06
JP2008503585A (ja) 2008-02-07
CA2571058A1 (en) 2006-01-05
CN101005838A (zh) 2007-07-25
EP1768667B1 (en) 2009-09-30
WO2006002133A1 (en) 2006-01-05
US20060100228A1 (en) 2006-05-11
HK1097189A1 (en) 2007-06-22
DE602005016929D1 (de) 2009-11-12

Similar Documents

Publication Publication Date Title
ES2332416T3 (es) Ligandos de receptores cannabinoides.
ES2303599T3 (es) Agonistas de los receptores de cannabinoides.
US7642272B2 (en) Cannabinoid receptor ligands
US7071213B2 (en) Cannabinoid receptor ligands
WO2010039982A1 (en) Crth2 modulators
CN110041327A (zh) 吡啶酮衍生物、其组合物及作为抗流感病毒药物的应用
JP2010059169A (ja) カンナビノイドレセプターリガンド
HK1097189B (en) Cannabinoid receptor ligands
ES2327763T3 (es) Heterociclilos utilizados como antagonistas del receptor de la hormona concentrada de melanina para el tratamiento de la obesidad y trastornos relacionados.
HK1074040B (en) Cannabinoid receptor ligands